dx 8951

Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL).Exatecan has antitumor activity and may be used in cancer research.

MC-GGFG-DX8951 (MC-GGFG-Exatecan) is an antibody-coupled drug (ADC) drug-linker conjugate (DLC) consisting of DX8951, a potent DNA topoisomerase I inhibitor, the linker MC, and the cleavable peptide chain GGFG, and has antitumor potential.

DBCO-PEG4-GGFG-DX8951 is a click-reactive Drug-linker that contains a DBCO group and can undergo a strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing an Azide group. DX8951 is a DNA topoisomerase I (topoisomerase I) inhibitor. DBCO-PEG4-GGFG-DX8951 can be used in the synthesis of antibody-drug conjugates (ADCs).

Py-MAA-Val-Cit-PAB-DX8951, a purine toxin, serves as an intermediate in the synthesis of antibody-drug conjugates [1].

Mal-Exatecan (Mal-DX-8951) is a malonamide (Mal)-modified antibody-drug conjugate used for preparing ADCs (antibody-drug conjugates) and studying cancer. Exatecan is an effective topoisomerase I inhibitor

DX-8951 Hydroxy-acid sodium is a prodrug of the phosphoramide class. It effectively elevates intracellular ATP levels and activates the AMPK signaling pathway by increasing the AMP/ATP ratio. Additionally, DX-8951 Hydroxy-acid sodium enhances mitochondrial function and antioxidant capacity while reducing reactive oxygen species (ROS) levels. It has demonstrated significant anti-aging and longevity effects in human fibroblast and C. elegans models.

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) consists of a cytotoxin, the topoisomerase I inhibitor DX-8951, and a linker sensitive to cathepsin, forming a drug-linker conjugate for antibody-drug conjugates (ADCs).

Val-Cit-PAB-Exatecan TFA (Val-Cit-PAB-DX8951 TFA) forms part of an antibody-drug conjugate (ADC). The compound consists of the DNA topoisomerase I inhibitor DX-8951 and a protease-degradable ADC linker.

ProAX is a prodrug of phosphoamide. It effectively elevates intracellular ATP levels and activates the AMPK signaling pathway by increasing the AMP/ATP ratio. ProAX enhances mitochondrial function and boosts antioxidant capacity while reducing reactive oxygen species (ROS) levels. It demonstrates significant anti-aging and longevity effects in human fibroblasts and nematode models.

Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA) is a derivative of Exatecan and serves as an anticancer agent. It exhibits significant antitumor activity and can be utilized in research related to cancer, such as solid tumors.

Ac-Exatecan (Ac-DX-8951) is acetylation-modified Exatecan.Exatecan (DX-8951) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM and antitumor activity.

Exatecan mesylate dihydrate (DX-8951), a DNA topoisomerase I inhibitor, exhibits an IC50 of 2.2 μM (0.975 μg/mL) and is utilized in cancer research [1] [2] [3].

(9R)-Exatecan (DX8951f) is the (1R,9S) stereoisomer of Exatecan. Exatecan (DX-8951) functions as a DNA topoisomerase I (topoisomeraseI) inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and is utilized in cancer research.

(1R,9S)-Exatecan (DX8951f) is the (1R,9S) stereoisomer of Exatecan. Exatecan (DX-8951) functions as an inhibitor of DNA topoisomerase I (topoisomerase I), with an IC50 of 2.2 μM (0.975 μg/mL), and is applicable in cancer research.

Glycyl-Exatecan (Glycyl-DX-8951) is the active metabolite released from DE-310 through enzymatic cleavage of the spacer. It exhibits antitumor activity in vivo and can be used in research on solid tumors.

Exatecan Mesylate (DX8951f) is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.

MC-VA-PAB-Exatecan is a part of the antibody-conjugated active molecule ADC. MC-VA-PAB-Exatecan is formed by coupling the cleavable ADC linker MC-VA-PAB with the payload Exatecan and is therefore used in antibody–drug conjugate development research systems. MC-VA-PAB-Exatecan is applied in ADC design studies to evaluate linker stability, payload release kinetics, and targeted cytotoxic delivery mechanisms in cancer cell models.

Exatecanintermediate 8 serves as an intermediate in the synthesis of Exatecan. Exatecan (DX-8951) is a commonly used cytotoxin component in ADC (Antibody-Drug Conjugate) preparation, and it functions as an inhibitor of DNA topoisomerase I (IC50=2.2 μM).

Exatecanintermediate 10 serves as an intermediate in synthesizing Exatecan. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), utilized for cancer research.

Exatecan Intermediate 3 is an intermediate of Exatecan. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), and it is utilized in cancer research. Exatecan Intermediate 3 can be employed in the synthesis of Antibody-Drug Conjugates (ADCs).

Exatecanintermediate 11 is an intermediate compound used in the synthesis of Exatecan. Exatecan (DX-8951) is a frequently utilized cytotoxic component in the preparation of antibody-drug conjugates (ADC Cytotoxin) and serves as an inhibitor of DNA topoisomerase I (topoisomeraseI) with an IC50 of 2.2 μM.

Antitumor agent-203 (compound 26) is a derivative of Exatecan (DX-8951) and serves as an ADC cytotoxin for antibody-drug conjugate (ADC) preparation.

Exatecananalog 13 is a homolog of Exatecan. Exatecan (DX-8951) is commonly used as a cytotoxic component in the preparation of antibody-drug conjugates (ADC) and acts as an inhibitor of DNA topoisomerase I (topoisomeraseI) with an IC50 of 2.2 μM.